Abraham Chachoua, MD, discusses some challenges of treating patients with lung cancer.
Abraham Chachoua, MD, director, Thoracic Oncology Research Program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, discusses some challenges of treating patients with lung cancer.
Learn about early detection and molecular testing in NSCLC > >
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
March 26th 2024According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More